Reduced Dose BCG in an Era of BCG Shortage: Real-World Experience from a Tertiary Cancer Centre.

Niyati LoboKelly K BreePatrick J HensleyGraciela M Nogueras-GonzalezPrasanth AbrahamNeema NavaiColin P DinneyAshish M Kamat

Published in: BJU international (2021)

The use of 1/3D BCG was not associated with adverse oncological outcomes in a large cohort of patients receiving adequate BCG for intermediate- and high-risk NMIBC. Based on this real-world experience, risk-stratified split-vial dosing may represent a valuable approach for other institutions facing BCG shortages whilst also providing reassurance to patients who may be concerned about suboptimal outcomes.

Keyphrases

papillary thyroid
squamous cell carcinoma
adipose tissue
skeletal muscle
metabolic syndrome
young adults
radical prostatectomy
weight loss
glycemic control
adverse drug
insulin resistance
drug induced